Market Research Logo

Cognitive Impairment - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Overview
Therapeutics Development
Pipeline Products for Cognitive Impairment - Overview
Pipeline Products for Cognitive Impairment - Comparative Analysis
Cognitive Impairment - Therapeutics under Development by Companies
Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
Cognitive Impairment - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cognitive Impairment - Products under Development by Companies
Cognitive Impairment - Products under Investigation by Universities/Institutes
Cognitive Impairment - Companies Involved in Therapeutics Development
AbbVie Inc.
Actinogen Limited
Addex Therapeutics Ltd
Amarantus Bioscience Holdings, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Avineuro Pharmaceuticals, Inc.
Avraham Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cardax Pharmaceuticals, Inc.
CereSpir Incorporated
Cognition Therapeutics, Inc.
D-Pharm Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
Evotec AG
F. Hoffmann-La Roche Ltd.
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Impel NeuroPharma, Inc.
Intra-Cellular Therapies, Inc.
Iproteos S.L.
Merck & Co., Inc.
Mnemosyne Pharmaceuticals, Inc.
Neuralstem, Inc.
Neuron Biopharma SA
Octapharma AG
Omeros Corporation
Pacific Northwest Biotechnology, LLC
Panacea Pharmaceuticals, Inc.
Pfizer Inc.
Pherin Pharmaceuticals, Inc.
Sage Therapeutics
Saniona AB
Shire Plc
Siena Biotech S.p.A.
SK Biopharmaceuticals Co., Ltd.
Sunovion Pharmaceuticals Inc.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Upsher-Smith Laboratories, Inc.
Vanda Pharmaceuticals Inc.
Vicore Pharma AB
Virogenomics, Inc.
Cognitive Impairment - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-431404 - Drug Profile
ADX-92639 - Drug Profile
AN-761 - Drug Profile
AP-61 - Drug Profile
AQW-051 - Drug Profile
ASP-4345 - Drug Profile
ASP-5736 - Drug Profile
AUT-1 - Drug Profile
AUT-6 - Drug Profile
AUT-9 - Drug Profile
AVL-3288 - Drug Profile
AVN-211 - Drug Profile
BAN-2401 - Drug Profile
BCA-909 - Drug Profile
BI-409306 - Drug Profile
BNC-375 - Drug Profile
C-21 - Drug Profile
CDX-085 - Drug Profile
CSP-1103 - Drug Profile
CT-0093 - Drug Profile
DAOI-B - Drug Profile
DP-NDD - Drug Profile
Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
DSP-3748 - Drug Profile
E-1R - Drug Profile
eltoprazine - Drug Profile
encenicline hydrochloride - Drug Profile
erteberel - Drug Profile
EVT-501 - Drug Profile
HTL-9936 - Drug Profile
IB-AD - Drug Profile
IC-041 - Drug Profile
idursulfase - Drug Profile
immune globulin (human) - Drug Profile
insulin (human) - Drug Profile
IPR-001 - Drug Profile
IPR-088 - Drug Profile
IPR-19 - Drug Profile
irdabisant - Drug Profile
ITI-214 - Drug Profile
JAY-22233 - Drug Profile
ladostigil tartrate - Drug Profile
levetiracetam - Drug Profile
LS-1137 - Drug Profile
LUAF-64280 - Drug Profile
LY-3002813 - Drug Profile
NPS-0158 - Drug Profile
NS-9283 - Drug Profile
NSI-189 - Drug Profile
NSP-0163 - Drug Profile
NST-0037 - Drug Profile
NST-0076 - Drug Profile
NST-0078 - Drug Profile
O-1966 - Drug Profile
PAN-811 - Drug Profile
PF-04958242 - Drug Profile
PH-15 - Drug Profile
PNU-120596 - Drug Profile
RO-4938581 - Drug Profile
roflumilast - Drug Profile
RTL-551 - Drug Profile
SEN-15924 - Drug Profile
sepranolone - Drug Profile
SKL-15508 - Drug Profile
SKL-A4R - Drug Profile
Small Molecule 1 for Cognitive Impairment - Drug Profile
Small Molecule 10 for Cognitive Impairment - Drug Profile
Small Molecule 11 for Cognitive Impairment - Drug Profile
Small Molecule 12 for Cognitive Impairment - Drug Profile
Small Molecule 2 for Cognitive Impairment - Drug Profile
Small Molecule 3 for Cognitive Impairment - Drug Profile
Small Molecule 4 for Cognitive Impairment - Drug Profile
Small Molecule 5 for Cognitive Impairment - Drug Profile
Small Molecule 6 for Cognitive Impairment - Drug Profile
Small Molecule 7 for Cognitive Impairment - Drug Profile
Small Molecule 8 for Cognitive Impairment - Drug Profile
Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile
Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile
Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile
Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile
Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile
Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
Small Molecules to Agonize GABA alpha 5 for Cognitive Impairment - Drug Profile
Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile
Small Molecules to Agonize NMDA2B for CIAS - Drug Profile
Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile
SUVN-501 - Drug Profile
SUVN-502 - Drug Profile
SUVN-507 - Drug Profile
SUVN-512 - Drug Profile
SUVN-976 - Drug Profile
TAK-058 - Drug Profile
TAK-915 - Drug Profile
tropisetron hydrochloride - Drug Profile
UE-2343 - Drug Profile
VU-0092273 - Drug Profile
xamoterol fumarate - Drug Profile
Cognitive Impairment - Recent Pipeline Updates
Cognitive Impairment - Dormant Projects
Cognitive Impairment - Discontinued Products
Cognitive Impairment - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cognitive Impairment, H2 2015
Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2015
Cognitive Impairment - Pipeline by AbbVie Inc., H2 2015
Cognitive Impairment - Pipeline by Actinogen Limited, H2 2015
Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2015
Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Cognitive Impairment - Pipeline by Astellas Pharma Inc., H2 2015
Cognitive Impairment - Pipeline by AstraZeneca Plc, H2 2015
Cognitive Impairment - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015
Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2015
Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2015
Cognitive Impairment - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2015
Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H2 2015
Cognitive Impairment - Pipeline by D-Pharm Ltd., H2 2015
Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2015
Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2015
Cognitive Impairment - Pipeline by Evotec AG, H2 2015
Cognitive Impairment - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
Cognitive Impairment - Pipeline by H. Lundbeck A/S, H2 2015
Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H2 2015
Cognitive Impairment - Pipeline by Impel NeuroPharma, Inc., H2 2015
Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
Cognitive Impairment - Pipeline by Iproteos S.L., H2 2015
Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2015
Cognitive Impairment - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015
Cognitive Impairment - Pipeline by Neuralstem, Inc., H2 2015
Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2015
Cognitive Impairment - Pipeline by Octapharma AG, H2 2015
Cognitive Impairment - Pipeline by Omeros Corporation, H2 2015
Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015
Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Cognitive Impairment - Pipeline by Pfizer Inc., H2 2015
Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015
Cognitive Impairment - Pipeline by Sage Therapeutics, H2 2015
Cognitive Impairment - Pipeline by Saniona AB, H2 2015
Cognitive Impairment - Pipeline by Shire Plc, H2 2015
Cognitive Impairment - Pipeline by Siena Biotech S.p.A., H2 2015
Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015
Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2015
Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Cognitive Impairment - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Cognitive Impairment - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015
Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H2 2015
Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2015
Cognitive Impairment - Pipeline by Virogenomics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2015
Cognitive Impairment - Dormant Projects, H2 2015
Cognitive Impairment - Dormant Projects (Contd..1), H2 2015
Cognitive Impairment - Dormant Projects (Contd..2), H2 2015
Cognitive Impairment - Dormant Projects (Contd..3), H2 2015
Cognitive Impairment - Dormant Projects (Contd..4), H2 2015
Cognitive Impairment - Dormant Projects (Contd..5), H2 2015
Cognitive Impairment - Dormant Projects (Contd..6), H2 2015
Cognitive Impairment - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Cognitive Impairment, H2 2015
Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Cognitive Impairment - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2015’, provides an overview of the Cognitive Impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;